The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.
Heikki Joensuu
Research Funding - Bayer; Novartis
Paolo Giovanni Casali
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Bayer; Novartis; Pfizer
Peter Reichardt
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Yoon-Koo Kang
Consultant or Advisory Role - Bayer; Novartis
Honoraria - Novartis
Research Funding - Bayer; Novartis
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - Merck Sharp & Dohme (U)
Piotr Rutkowski
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Hans Gelderblom
No relevant relationships to disclose
Peter Hohenberger
No relevant relationships to disclose
Michael Gordon Leahy
No relevant relationships to disclose
Margaret von Mehren
No relevant relationships to disclose
Giuseppe Badalamenti
No relevant relationships to disclose
Martin E. Blackstein
Research Funding - Bayer
Axel Le Cesne
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Patrick Schoffski
No relevant relationships to disclose
Robert G. Maki
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Novartis
Jian-Ming Xu
No relevant relationships to disclose
Toshirou Nishida
Consultant or Advisory Role - Novartis
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Novartis
Christian Kappeler
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Iris Kuss
Employment or Leadership Position - Bayer
George D. Demetri
Consultant or Advisory Role - ARIAD; Bayer; Blueprint Medicines; Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals; Merck; Merrimack; N-of-One ; Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - Bayer; GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - Bayer; GlaxoSmithKline; Johnson & Johnson; Merck